Ardelyx, Inc. (ARDX) NASDAQ

5.53

-0.2014(-3.51%)

Updated at June 02 03:27PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Michael G. Raab	President, Chief Executive Officer & Director	1.43M	1965
Sue Hohenleitner	Chief Financial Officer	507,345	1971
John Bishop	Chief Technical & Quality Officer	599,510	1962
Mike Kelliher	Chief Business Officer	622,498	1977
Rajani Dinavahi	Chief Medical Officer	664,810	N/A
Elizabeth A. Grammer	General Counsel	724,423	1964
Laura A. Williams	Chief Patient Officer & Interim Chief Medical Officer	739,126	1963
Eric Duane Foster	Chief Commercial Officer	0	1975
Caitlin Lowie	Vice President of Corporate Communications & Investor Relations	0	N/A
Felecia W. Ettenberg	Chief Legal Officer	0	1971
James Brady	Chief Human Resources Officer	0	1971
Joseph Reilly	Senior Vice President of Finance & Principal Accounting Officer	0	1974

Name

Title

Pay

Year Born

Michael G. Raab

President, Chief Executive Officer & Director

1.43M

1965

Sue Hohenleitner

Chief Financial Officer

507,345

1971

John Bishop

Chief Technical & Quality Officer

599,510

1962

Mike Kelliher

Chief Business Officer

622,498

1977

Rajani Dinavahi

Chief Medical Officer

664,810

N/A

Elizabeth A. Grammer

General Counsel

724,423

1964

Laura A. Williams

Chief Patient Officer & Interim Chief Medical Officer

739,126

1963

Eric Duane Foster

Chief Commercial Officer

1975

Caitlin Lowie

Vice President of Corporate Communications & Investor Relations

N/A

Felecia W. Ettenberg

Chief Legal Officer

1971

James Brady

Chief Human Resources Officer

1971

Joseph Reilly

Senior Vice President of Finance & Principal Accounting Officer

1974

Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.